What stands between people and cancer screening
Overview
The cancer questions show a clear gap between interest in screening and concern about the cost of care.
Adults broadly value noninvasive multi-cancer early detection tests, but the same cluster shows strong concern about the financial impact if cancer care is needed.
Stacked breakdown
74.9% call these tests very important for the healthcare system.
How important is it for the healthcare system to offer noninvasive multi-cancer early detection tests (e.g., Galleri, Cologuard)?
- Not at all important
- 2.5%
- Somewhat important
- 22.6%
- Very important
- 74.9%
Screening interest is high
A 74.9% share said it is very important for the healthcare system to offer noninvasive multi-cancer early detection tests.
Another 67.0% said they would be somewhat or very likely to complete one of these tests.
Stacked breakdown
81.3% say they would likely act on test results.
How likely are you to take action based on the results of a noninvasive multi-cancer early detection tests (e.g., Galleri, Cologuard)?
- Very unlikely
- 1.5%
- Somewhat unlikely
- 2.7%
- Neutral
- 14.6%
- Somewhat likely
- 29.3%
- Very likely
- 52.0%
Trust and follow-through shape the story
A 61.4% share agreed that they would trust the results of these tests as much as traditional cancer screening at a doctor's office.
An 81.3% share said they would be somewhat or very likely to take action based on the results.
Stacked breakdown
72.7% are very or extremely concerned about cancer-care costs.
If you or someone in your household needed cancer care, how concerned would you be about the financial impact on your household?
- Not at all concerned
- 3.4%
- Slightly concerned
- 6.6%
- Moderately concerned
- 15.9%
- Very concerned
- 25.7%
- Extremely concerned
- 47.0%
- Other
- 1.4%
Cost concern remains high
A 72.7% share said they would be very or extremely concerned about the household financial impact if they or someone in their household needed cancer care.
Methodology
Full methodology- Mode
- Verasight panel recruited via random address-based sampling, random person-to-person text messaging, and dynamic online targeting
- Population
- US adults age 18+
- Field dates
- 2026-05-01 → 2026-05-04
- Base (unweighted)
- 1,000
- Margin of error
- +/- 3.3%
- Module
- 2
- Sponsor
- Verasight
- Weight variable
- weight
- Weighting targets
- age, race/ethnicity, sex, income, education, region, metropolitan status
Sources
[5]- 01How important is it for the healthcare system to offer noninvasive multi-cancer early detection tests (e.g., Galleri, Cologuard)?Three-quarters said it is very important for the healthcare system to offer noninvasive multi-cancer early detection tests.reports.verasight.io/reports/sbm-2026
- 02How likely are you to complete a noninvasive multi-cancer early detection test (e.g., Galleri, Cologuard)?About two-thirds said they would be somewhat or very likely to complete a noninvasive multi-cancer early detection test.reports.verasight.io/reports/sbm-2026
- 03To what extent do you agree or disagree with the following statement: "I would trust the results of noninvasive multi-cancer early detection tests (e.g., Galleri, Cologuard) as much as a traditional cancer screening at my doctor's office."About six-in-ten said they would trust the results of these tests as much as traditional cancer screening at a doctor's office.reports.verasight.io/reports/sbm-2026
- 04How likely are you to take action based on the results of a noninvasive multi-cancer early detection tests (e.g., Galleri, Cologuard)?More than eight-in-ten said they would be somewhat or very likely to take action based on test results.reports.verasight.io/reports/sbm-2026
- 05If you or someone in your household needed cancer care, how concerned would you be about the financial impact on your household?Nearly three-quarters said they would be very or extremely concerned about the household financial impact of cancer care.reports.verasight.io/reports/sbm-2026
Citation
SBM Omnibus Survey #2026-049, fielded May 1-4, 2026, N=1,000 US adults age 18+, +/- 3.3%.